Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Stock analysts at William Blair reduced their Q4 2024 earnings per share estimates for Charles River Laboratories International in a report issued on Thursday, November 7th. William Blair analyst M. Smock now expects that the medical research company will post earnings of $2.46 per share for the quarter, down from their prior estimate of $2.57. The consensus estimate for Charles River Laboratories International's current full-year earnings is $10.20 per share. William Blair also issued estimates for Charles River Laboratories International's Q1 2025 earnings at $2.41 EPS, Q4 2025 earnings at $2.85 EPS and FY2025 earnings at $10.59 EPS.
Other analysts have also issued reports about the stock. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday. UBS Group upped their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a report on Thursday. Robert W. Baird reduced their price target on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a report on Friday, September 20th. The Goldman Sachs Group cut their price objective on Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. Finally, Bank of America lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $217.54.
Get Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Stock Up 2.5 %
Shares of Charles River Laboratories International stock traded up $5.30 on Monday, reaching $220.69. 774,498 shares of the company were exchanged, compared to its average volume of 616,718. The company has a market capitalization of $11.29 billion, a price-to-earnings ratio of 27.60, a PEG ratio of 5.80 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.21 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a one year low of $168.24 and a one year high of $275.00. The company has a 50-day moving average of $193.91 and a 200 day moving average of $208.05.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm's revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $2.72 earnings per share.
Charles River Laboratories International announced that its Board of Directors has approved a share buyback plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.
Hedge Funds Weigh In On Charles River Laboratories International
Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company's stock valued at $1,638,290,000 after acquiring an additional 66,161 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 1.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock valued at $394,359,000 after purchasing an additional 31,359 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Clearbridge Investments LLC increased its position in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company's stock worth $409,985,000 after purchasing an additional 45,079 shares in the last quarter. Finally, Meritage Group LP lifted its stake in Charles River Laboratories International by 2.3% in the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company's stock valued at $320,336,000 after purchasing an additional 26,892 shares during the last quarter. Institutional investors own 98.91% of the company's stock.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Further Reading
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.